Publication: 3 years real-world results with the Inreda AP®

In our latest publication in the journal Diabetes Technology & Therapeutics, we analyzed long-term data from 102 Inreda AP® users.

The study results show that the performance of the fully closed-loop Inreda AP® remained stable for 3 years in users treated with the original glucagon (GlucaGen). This is the first time such an effect has been observed with a diabetes treatment.

Of the total group of 102 people, 60 were treated exclusively with this glucagon (Figure A), while the remaining AP® users had to switch to an alternative glucagon (Glugon) due to availability issues (Figure B). This alternative glucagon appeared to have a negative effect on AP® treatment. This was confirmed by a significant deterioration in AP® control after the switch in glucagon compared with the period before the switch.

The three-year long-term results of AP® use underscore the value of the Inreda AP® in maintaining good glucose control over time in people with type 1 diabetes.

Read the full publication here: Three-Year Real-World Performance of Bihormonal Fully Closed-Loop Therapy in Type 1 Diabetes – Theodorus J.P. Jansen, Carmen den Drijver, Lyan B. Vlaskamp, Arianne C. van Bon, 2026

A summary of the key findings is available to download here: